ID   LS174T/R
AC   CVCL_A5BI
SY   LS 174T/R
DR   cancercelllines; CVCL_A5BI
DR   Wikidata; Q107115875
RX   PubMed=12606785;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP).
CC   Sequence variation: Mutation; HGNC; 2514; CTNNB1; Simple; p.Ser45Phe (c.134C>T); ClinVar=VCV000017588; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000012582; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.His1047Arg (c.3140A>G); ClinVar=VCV000013652; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
CC   Cell type: Epithelial cell of colon; CL=CL_0011108.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1384 ! LS174T
SX   Female
AG   58Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=12606785; DOI=10.1124/mol.63.3.742;
RA   Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Usefulness of liposomes loaded with cytostatic bile acid derivatives
RT   to circumvent chemotherapy resistance of enterohepatic tumors.";
RL   Mol. Pharmacol. 63:742-750(2003).
//